Nattopharma spearheads effort to establish RDI for vitamin K2

By Hank Schultz

- Last updated on GMT

Nattopharma spearheads effort to establish RDI for vitamin K2
Nattopharma has joined with Dutch researchers in an effort to establish an officially recognized level for vitamin K2 consumption.

Nattopharma is a Norwegian firm that pioneered a naturally fermented form of the vitamin, branded as MenaQ7. Vitamin K2 can be found in foods such as natto, a gooey, fermented soybean paste from Japan and naturally fermented cheeses.

Nattopharma’s Eric Anderson, senior vice president of global marketing and business development, said the company will be cooperating with a team from Maastricht University in the Netherlands to help establish an RDI (Reference Daily Intake) level for the vitamin, which is important in bone health and cardiovascular health. Anderson said the company has kicked around the RDI idea for a while.

“We have been exploring this for some time. We’re members of CRN (the Council for Responsible Nutrition) and have talked to them about this, too,”​ Anderson told NutraIngredients-USA.

“It’s an arduous process. You have to have enough evidence of what people are eating and therefore not getting enough of a certain compound. You have to have data to prove that there is not enough of that compound in the typical diet,”​ he said.

Culmination of two decades of work

The team of researchers is headed by longtime Nattopharma collaborator Leon Schurgers, PhD. Schurgers’ team has secured a Horizon 2020 grant to fund the work of a group of PhD candidates to assemble the data on K2.

One of their tasks will be to clearly lay out the differences between vitamins K1 and K2. Many labels still just call out ‘vitamin K,’ which fails to delineate critical functional differences between the phylloquinone (K1) form and menaquinone (K2) form. K1 is associated with the clotting of blood, which was Schurgers’ point of entry when he started work on the vitamin more than 20 years ago. But K2’s effects go far beyond mere clotting factors, Anderson said.  

Research done by Schurgers and sponsored by Nattopharma has shown that K2 has a critical function in bone health by regulating the mobility of calcium into and out of the bones. And K2 has further been shown to have a role in helping to restrict the deposition of calcium in the form of arterial plaques or in stiffening arterial walls, thus contributing to cardiovascular health.  Anderson said Nattopharma is adding to the Horizon 2020 grant to build the dossier that lays out this case.

“We are sponsoring a group of four PhD candidates under Dr Schurgers’ direction to look at the category to see what the needs are in terms of intake and to establish the fundamental explanation of how K1 and K2 are different, and why there is a special need to establish an RDI for K2,”​ Anderson said.

“We are under no illusions about how quickly this might happen. Beyond the research, you have to have someone who will champion the cause with government. It helps to have an academic champion, as has happened with choline and lutein,”​ he said.

Foundation supports K2 effort

Schurgers’ team will be joined by the International Science and Health Foundation (ISHF), a research consortium responsible for the educational portal According to Katarzyna Maresz, PhD, ISHF president, ​ was specifically created to educate consumers and practitioners about the proven benefits of Vitamin K2, recognizing the impact of widespread K2 deficiency. 

“We have seen in comprehensive studies — in adults as well as children — that correcting Vitamin K2 deficiency can greatly improve bone health, and studies in adults have delivered unprecedented improvement in cardiovascular health,”​ she said. “Yet studies also show that 97% of the Western population remains deficient. Establishing an RDI is an important step in educating the public about their absolute dietary need, providing them much-needed direction.”  

Maresz said having a validated biomarker or clinical endpoint is a key to the process of establishing an RDI. It’s necessary to have a way to measure the consequences of inadequate K2 consumption. Maresz said inactive Matrix Gla Protein (dpucMGP) or the ratio of inactive to inactive Osteocalcin (ucOC/cOC) — both proteins activated by K2 — could be used as markers of vitamin K2 status.

Related news

Show more

Related products

show more

Standard-Form & Functionally Optimized Nutrients

Standard-Form & Functionally Optimized Nutrients

Glanbia Nutritionals | 09-Mar-2023 | Product Brochure

Whether you’re looking to source the standard form of a nutrient or need a version that performs at its best in your product application, we have a robust...

Related suppliers

1 comment

A previous request the Commissioner of the FDA to issue adequate intake levels for vitamin K2

Posted by David K Cundiff,

Before submitting your petition to have an RDI for vitamin K2 to the FDA in the USA, you might look at my petition about an RDI for vitamin K2 submitted almost 2 years ago:

It begins:
Citizen Petition: Requesting that the Food and
Drug Administration establish “adequate
intake” levels (AIs) for vitamin K2
August 25, 2016, Date
The undersigned submits this petition under sections 21 C.F.R. 10.20 and 10.30 of the
Federal Food, Drug, and Cosmetic Act to request the Commissioner of Food and Drugs to
issue adequate intake levels for vitamin K2.
A. Action Requested by Citizen Petition
Please issue adequate intakes (AIs) for vitamin K2 (menaquinones: MK-4 – MK-13) for
USA residents of all ages:
(1) The FDA has not heretofore issued AIs for vitamin K2 or any statement to the effect
that AIs for vitamin K2 are not in the interest of individuals or the public health.
(2) The recommendation for the FDA to establish vitamin K2 AIs are according to the
age groups in Table 1:

Report abuse

Follow us

Featured Events

View more


View more